IDWeek 2018

Once-daily single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in adults who have virologic suppression of HIV-1 infection has a high efficacy and safety profile.

PCV13 in adults age <65 years with diabetes could reduce a substantial number of pneumonia hospitalizations.

No significant differences in clinical cure rates were observed between short-course and prolonged-course antimicrobial therapy in patients with intraabdominal infections.

Treatment for hepatitis C is associated with a reduction in cardiovascular events.

Vitamin D deficiency is associated with increased risk for sepsis mortality in postmenopausal women, which was seen in all ages.

For patients with CAP, antibiotic regimens including a fluoroquinolone may reduce mortality risk by 1-2% compared to beta-lactams and cephalosporins alone.

Analysis of 2 phase 3 clinical trials evaluating the safety/efficacy of glecaprevir/pibrentasvir in people with HCV coinfected with HIV-1 found an overall sustained virologic response of 98% at week 12 of treatment in those with or without cirrhosis.

Incidence of body fat redistribution/accumulation, pancreatic disorders, musculoskeletal disorders, IRIS, severe systemic rash, and HSR did not differ among common prescribed antiretrovirals.

Treatment with intravenous and oral delafloxacin, a fluoroquinolone antibiotic with gram-negative and gram-positive activity, was comparable to vancomycin/aztreonam in improving clinical signs and symptoms in acute bacterial and skin structure infections.

In patients taking multiple antibiotics, proton pump inhibitors, or histamine receptor antagonists, the concurrent use of probiotics was associated with an increased incidence of Clostridium difficile infection